Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:VERA 11 December 2025 - 30 December 2025

Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition

Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition

Vera Therapeutics shares fell 2.6% to $54.24 midday Friday in thin post-holiday trading, with no major news driving the move. The stock has recently digested a Biologics License Application filing for atacicept in IgA nephropathy, a resolved public offering, and increased competition in the IgAN market. Trading volume remained light, typical for the year-end period.
26 December 2025
Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets

Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets

Vera Therapeutics shares traded near $46 on December 11, 2025, after announcing a $261 million stock offering at $42.50 per share. The company filed a Biologics License Application for atacicept in IgA nephropathy and reported strong late-stage clinical results. Shares are up nearly 100% in six months, with market cap around $2.9–3.0 billion. The offering is expected to close today.
11 December 2025
·

Stock Market Today

  • Centene Launches Community Programs Amid Depressed Stock Price: What Investors Should Know
    March 20, 2026, 6:30 AM EDT. Centene Corp subsidiaries have initiated community-focused programs targeting behavioral health, job training, housing support, and diabetes care, aiming to assist underserved populations across major U.S. markets. These efforts come as Centene shares (NYSE:CNC) remain under pressure, with a recent price of $35.57, down 13.7% in the past month and 40.3% over one year. Investors should monitor these initiatives closely for insights into Centene's regulatory relations and potential impact on medical loss ratios and membership retention. Despite current headwinds, the stock trades nearly 17% below analyst targets and is marked as undervalued by Simply Wall St. Key risks include rising costs without clear reimbursement or measurable health outcomes.
Go toTop